PGIM India Mutual Fund
When comparing, both lines start at 100. Tradinity's reference for the category: a total-return index (dividends reinvested). The fund's declared benchmark (BSE Healthcare TRI) is not available to us as a series.
Up to one year: absolute. Longer: annualised. Category = median of Sectoral/Thematic direct-plan Growth funds; index = NIFTY 500 TRI.
| Period | This fund | Category median | NIFTY 500 TRI | Rank in category |
|---|---|---|---|---|
| 1 month | -2.78% | -5.43% | -6.32% | — |
| 3 months | +5.70% | -2.83% | -5.14% | — |
| 6 months | +25.15% | +8.81% | +5.07% | — |
| 1 year | +25.67% | +1.34% | -3.80% | #6 of 224 Top 3% |
| 3 years | — | +12.83% | +9.14% | — |
| 5 years | — | +11.70% | +8.89% | — |
| 10 years | — | +14.63% | +12.66% | — |
| Since launch of NAV data | +11.98% | — | — | — |
| Window | High | Low |
|---|---|---|
| 1 month | 12.6300 | 12.2400 |
| 3 months | 12.7500 | 11.5800 |
| 6 months | 12.7500 | 9.6600 |
| 1 year | 12.7500 | 9.4200 |
A period is a dash when the fund has not existed that long or its NAV history has a hole at the start date — never a partial figure.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | YTD | |
|---|---|---|---|---|---|---|---|
| This fund | — | — | — | — | — | -0.99% | +22.16% |
| Category median | +14.76% | +32.13% | +5.11% | +32.77% | +22.00% | +4.37% | -2.14% |
| NIFTY 500 TRI | +17.89% | +31.60% | +4.25% | +26.91% | +16.24% | +7.76% | -7.72% |
Tradinity's reference for the category: a total-return index (dividends reinvested). The fund's declared benchmark (BSE Healthcare TRI) is not available to us as a series.
Twenty checks of five points each: performance, portfolio, operations, and risk against reward. Only checks we have data for are counted.
Risk-free rate 6.06% (3-year annualised return of the NSE 1-day (overnight) rate index). Benchmark-relative ratios use NIFTY 500 TRI. Tradinity's reference for the category: a total-return index (dividends reinvested). The fund's declared benchmark (BSE Healthcare TRI) is not available to us as a series.
| Ratio | This fund | Category median | Against category |
|---|---|---|---|
| Sharpe ratio | — | 0.42 | — |
| Sortino ratio | — | 0.57 | — |
| Standard deviation | — | 15.72% | — |
| Maximum drawdown | — | -21.28% | — |
| Beta | — | 0.93 | — |
| R-squared | — | 82.5% | — |
| Jensen's alpha | — | 3.49% | — |
| Treynor ratio | — | 6.74 | — |
| Information ratio | — | 0.55 | — |
| Upside capture | — | 93.7% | — |
| Downside capture | — | 91.0% | — |
Computed from this fund's actual NAVs. A SIP buys at the first NAV of each month and is valued at the latest NAV. Past returns do not guarantee future ones.
Weights are % of the scheme's assets from the latest month-end disclosure available to Tradinity. The feed carries weights only: no quantities or rupee values.
Valuation ratios are weighted over the holdings we can match to a company (harmonic mean for P/E) and are withheld when they cover under half the portfolio.
| Holding | Sector | Weight | 3M change | P/E |
|---|---|---|---|---|
| Divi's Laboratories Ltd. | Healthcare | 10.85% | — | 83.0 |
| Sun Pharmaceutical Industries Ltd. | Healthcare | 10.74% | — | 143.5 |
| Torrent Pharmaceuticals Ltd. | Healthcare | 8.86% | — | 77.7 |
| Clearing Corporation of India Ltd. | — | 5.76% | — | — |
| Max Healthcare Institute Ltd. | Healthcare | 4.96% | — | 124.3 |
| Ajanta Pharma Ltd. | Healthcare | 4.83% | — | 43.2 |
| Manipal Health Enterprises Ltd. | Healthcare | 4.12% | — | — |
| Mankind Pharma Ltd. | Healthcare | 4.07% | — | 46.9 |
| Rubicon Research Ltd. | Healthcare | 4.01% | — | 111.0 |
| Dr. Lal Path Labs Ltd. | Healthcare | 3.93% | — | 38.4 |
| Neuland Laboratories Ltd. | Healthcare | 3.26% | — | 56.5 |
| Krishna Inst of Medical Sciences Ltd. | Healthcare | 3.15% | — | 105.1 |
| Navin Fluorine International Ltd. | Chemicals | 3.04% | — | 74.9 |
| Aster DM Quality Care Ltd. | Healthcare | 2.89% | — | 205.8 |
| Abbott India Ltd. | Healthcare | 2.83% | — | 34.5 |
| Sai Life Sciences Ltd | Healthcare | 2.54% | — | 89.9 |
| Cipla Ltd. | Healthcare | 2.23% | — | 35.1 |
| Pfizer Ltd. | Healthcare | 2.12% | — | 23.9 |
| Anthem Biosciences Ltd. | Healthcare | 1.96% | — | 76.6 |
| Jupiter Life Line Hospitals Ltd. | Healthcare | 1.77% | — | 9.0 |
| Global Health Ltd. | Healthcare | 1.72% | — | 74.4 |
| Zydus Lifesciences Ltd. | Healthcare | 1.51% | — | 32.6 |
| Lupin Ltd. | Healthcare | 1.42% | — | 13.2 |
| ICICI Lombard General Insurance Co. Ltd. | Financial Services | 1.40% | — | — |
| Dr Agarwal's Eye Hospital Ltd. | Healthcare | 1.20% | — | 32.8 |
| Fortis Healthcare Ltd. | Healthcare | 1.10% | — | 255.5 |
| Dr Agarwal's Health Care Ltd. | Healthcare | 0.86% | — | 334.0 |
| Orchid Pharma Ltd. | Healthcare | 0.80% | — | 143.5 |
| Gland Pharma Ltd. | Healthcare | 0.73% | — | 34.4 |
| Lenskart Solutions Ltd. | Consumer Services | 0.71% | — | 226.4 |
| IPCA Laboratories Ltd. | Healthcare | 0.51% | — | 39.8 |
| Sagility Ltd. | Information Technology | 0.46% | — | 60.8 |
This is a paid feature
Comparing more months of this fund's own portfolio history is available on paid plans.
Sign inExpense ratio by month: Oct 25 0.66% · Nov 25 0.65% · Dec 25 0.65% · Jan 26 0.65% · Feb 26 0.65% · Mar 26 0.65% · Apr 26 0.75% · May 26 0.80% · Jun 26 0.86% · Jul 26 0.92% · Aug 26 0.93% · Sep 26 0.96%
For Exits within 90 days from date of allotment of units: 0.50%; For Exits beyond 90 days from date of allotment of units: NIL.
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.; However, there is no assurance that the investment objective of the scheme will be achieved. The Scheme does not guarantee/ indicate any returns.
Fund house: · factsheets · monthly portfolio · annual report
Not available: Morningstar rating (proprietary). "NAV history from" is the first NAV we hold.
Returns are computed by Tradinity from each scheme's own published NAV, so they are net of the fund's expenses. Periods over one year are annualised (CAGR). Past performance does not indicate future returns. Only Growth-option schemes are ranked: an IDCW scheme pays cash out of its NAV, so its NAV understates what an investor earned.
